Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7710MR)

This product GTTS-WQ7710MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7710MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13624MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ14673MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ10460MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ5338MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ2464MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ2502MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ14991MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ2779MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-282
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW